title: Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFNalpha.
abstract: A 3-year-old girl with BCR/ABL-positive CML relapsed after related HLA-identical cord blood transplantation. She was treated with three cycles of donor lymphocyte (DLI) infusion from her 15-month-old brother. Interferon alpha was added after the second DLI, whereas a trial of IL-2 had to be discontinued because of increasing immature myeloid cells in the blood smear. No signs of GVHD were observed, but she developed myelosuppression and needed one platelet and one red blood cell transfusion. She achieved a molecular remission after 6 months with transient molecular relapse followed by sustained remission for 15 months. Thus, DLI with or without interferon alpha might prove to be a promising treatment option with tolerable side-effects in relapsed CML after cord blood transplantation. Bone Marrow Transplantation (2000) 25, 219-222.
authors.affiliation: Department of Pediatric Hematology and Oncology, Heinrich Heine University, Düsseldorf, Germany.
authors.forename: H J
authors.initials: HJ
authors.lastname: Laws
authors.forename: W
authors.initials: W
authors.lastname: Nürnberger
authors.forename: D
authors.initials: D
authors.lastname: Körholz
authors.forename: G
authors.initials: G
authors.lastname: Kögler
authors.forename: J
authors.initials: J
authors.lastname: Fischer
authors.forename: T
authors.initials: T
authors.lastname: Niehues
authors.forename: P
authors.initials: P
authors.lastname: Wernet
authors.forename: U
authors.initials: U
authors.lastname: Göbel
mesh_terms: D016913:Blood Component Transfusion / Q000009:adverse effects; D002675:Child, Preschool; D005260:Female; D005312:Fetal Blood; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000009:adverse effects; D008297:Male; D012008:Recurrence; D012074:Remission Induction
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D016044:Fusion Proteins, bcr-abl